<div id="readability-page-1">11:24 AM EST, 12/30/2025 (MT Newswires) -- Genmab ( GMAB ) can expect a &#34;transformative&#34; year ahead, with five to six pivotal trial readouts for Epkinly, Rina-S and petosemtamab, Truist Securities said in note Tuesday.The company's recent decision to discontinue development of acasunlimab was disappointing, but should result in savings of about $100 million, which is expected to be redirected to the Rina-S and petosemtamab programs, according to the note.Considering that pivotal studies are already being conducted for Rina-S in ovarian and endometrial cancer, and for petosemtamab in head and neck cancer, Truist said the realigned funds are expected to focus more on exploring other potential indications for these assets.The brokerage said it updated its model to remove the projected revenue for acasunlimab and add potential Rina-S revenue in endometrial cancer, with the first commercial contribution expected in 2029.Truist maintained a buy rating on the stock, with a $48 price target.Shares of Genmab ( GMAB ) were down more than 2% in recent trading Tuesday.Price: 31.77, Change: -0.76, Percent Change: -2.32 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

GMAB

根据 Truist Securities 的报告，Genmab 在未来一年有望迎来 “变革性” 的发展，预计将有五到六项关键试验结果发布。尽管停止开发 acasunlimab 令人失望，但公司将节省约 1 亿美元，并将资金重新分配到 Rina-S 和 petosemtamab 项目上。Rina-S 在卵巢癌和子宫内膜癌的关键研究正在进行中，而 petosemtamab 则在头颈癌方面进行研究。Truist 维持对该公司的买入评级，目标价为 48 美元，尽管 Genmab 的股价最近下跌超过 2%

Truist Securities 表示，Genmab 面临着一个'变革性'的一年，关键试验结果即将揭晓